Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT 1 COMBINATION PACK versus NILSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT 1 COMBINATION PACK versus NILSTAT.
MONISTAT 1 COMBINATION PACK vs NILSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death. Miconazole also has direct anti-inflammatory and antibacterial properties.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Miconazole nitrate 1200 mg vaginal suppository inserted intravaginally once at bedtime; plus external miconazole nitrate 2% cream applied to affected area twice daily for up to 7 days.
Topical: Apply 100,000 units/g cream or ointment to affected area twice daily. Oral suspension: 100,000 units/mL; 4-6 mL swish and swallow four times daily for 14 days. Oral tablets: 500,000 units; 1-2 tablets three times daily.
None Documented
None Documented
Terminal elimination half-life: 24-30 hours (range 20-50 hours). Clinical context: Once-daily dosing may be considered for some indications, but prolonged half-life supports weekly or twice-weekly regimens for systemic infections.
Not well-defined due to minimal systemic absorption following oral or topical administration; estimated to be <1 hour in systemic circulation if absorbed.
Fecal: Approximately 90% of absorbed dose; Renal: <2% as unchanged drug; Biliary: Minor, less than 10%.
Primarily via feces as unchanged drug; negligible urinary excretion (<1%).
Category C
Category C
Antifungal
Antifungal